PHBBF Quote, Financials, Valuation and Earnings

Hong Kong Pharma Digital Technology Holdings has a net margin of -- compared to Pharmaron Beijing's net margin of --. Pharmaron Beijing's return on equity of -- beat Hong Kong Pharma Digital Technology Holdings's return on equity of --.

Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand Hong Kong Pharma Digital Technology Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharmaron Beijing has higher upside potential than Hong Kong Pharma Digital Technology Holdings, analysts believe Pharmaron Beijing is more attractive than Hong Kong Pharma Digital Technology Holdings.

Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 1.46%. Hong Kong Pharma Digital Technology Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings pays out -- of its earnings as a dividend.

Pharmaron Beijing quarterly revenues are --, which are smaller than Hong Kong Pharma Digital Technology Holdings quarterly revenues of --. Pharmaron Beijing's net income of -- is lower than Hong Kong Pharma Digital Technology Holdings's net income of --. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while Hong Kong Pharma Digital Technology Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus -- for Hong Kong Pharma Digital Technology Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Prenetics Global has a net margin of -- compared to Pharmaron Beijing's net margin of -137.21%. Pharmaron Beijing's return on equity of -- beat Prenetics Global's return on equity of -23.16%.

Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global has an analysts' consensus of $13.00 which suggests that it could grow by 202.33%. Given that Prenetics Global has higher upside potential than Pharmaron Beijing, analysts believe Prenetics Global is more attractive than Pharmaron Beijing.

Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 1.46%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend.

Pharmaron Beijing quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $7.8M. Pharmaron Beijing's net income of -- is lower than Prenetics Global's net income of -$10.7M. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus 2.07x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.

Regencell Bioscience Holdings has a net margin of -- compared to Pharmaron Beijing's net margin of --. Pharmaron Beijing's return on equity of -- beat Regencell Bioscience Holdings's return on equity of --.

Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharmaron Beijing has higher upside potential than Regencell Bioscience Holdings, analysts believe Pharmaron Beijing is more attractive than Regencell Bioscience Holdings.

Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regencell Bioscience Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 1.46%. Regencell Bioscience Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. Regencell Bioscience Holdings pays out -- of its earnings as a dividend.

Pharmaron Beijing quarterly revenues are --, which are smaller than Regencell Bioscience Holdings quarterly revenues of --. Pharmaron Beijing's net income of -- is lower than Regencell Bioscience Holdings's net income of --. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while Regencell Bioscience Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus -- for Regencell Bioscience Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Sino Biopharmaceutical has a net margin of -- compared to Pharmaron Beijing's net margin of --. Pharmaron Beijing's return on equity of -- beat Sino Biopharmaceutical's return on equity of 10.53%.

Pharmaron Beijing has a consensus price target of --, signalling downside risk potential of --. On the other hand Sino Biopharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharmaron Beijing has higher upside potential than Sino Biopharmaceutical, analysts believe Pharmaron Beijing is more attractive than Sino Biopharmaceutical.

Pharmaron Beijing has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sino Biopharmaceutical has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.55%.

Pharmaron Beijing has a quarterly dividend of $0.03 per share corresponding to a yield of 1.46%. Sino Biopharmaceutical offers a yield of 2.42% to investors and pays a quarterly dividend of $0.00 per share. Pharmaron Beijing pays -- of its earnings as a dividend. Sino Biopharmaceutical pays out 27.13% of its earnings as a dividend. Sino Biopharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pharmaron Beijing quarterly revenues are --, which are smaller than Sino Biopharmaceutical quarterly revenues of --. Pharmaron Beijing's net income of -- is lower than Sino Biopharmaceutical's net income of --. Notably, Pharmaron Beijing's price-to-earnings ratio is -- while Sino Biopharmaceutical's PE ratio is 24.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmaron Beijing is 1.44x versus 2.03x for Sino Biopharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.